GSK To Shell Out $21.5M To Exit Wellbutrin Antitrust Suit

Law360, New York (January 14, 2013, 6:32 PM EST) -- A Pennsylvania federal judge on Monday signed off on a $21.5 million settlement between GlaxoSmithKline PLC and employee benefit plans in a class action alleging the pharmaceuticals giant filed sham patent suits to intentionally delay generic competition to its antidepressant Wellbutrin SR.

U.S. District Judge Lawrence F. Stengel granted preliminary approval on the settlement, which was first submitted to the court Dec. 21, between GSK and third-party payor plaintiffs who claimed GSK forced them to pay higher prices for antidepressant Wellbutrin SR and similar drug Zyban...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.